{"url_path":"/sec/bctx/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 Other Information.**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-06-09","source_url":"https://www.sec.gov/Archives/edgar/data/1610820/0001493152-26-027928-index.html","accession_number":"0001493152-26-027928","cik":"0001610820","ticker":"BCTX","issuer_name":"BriaCell Therapeutics Corp.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1610820/0001493152-26-027928-index.html","primary_entity_key":"0001610820","primary_entity_name":"BriaCell Therapeutics Corp."},"word_count":43,"has_tables":true,"body_markdown":"**Item\n5. Other Information.**\n\n \n\nDuring the three months ended April\n30 2026, no director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement”\nor “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K."}